A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs F8 IL10 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 16 Jun 2018 Updated results of Dekavil of phase 1 and phase 2 studies presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 05 Jan 2018 The study has been discontinued in Germany.
    • 08 Nov 2017 Results of phase Ib trial (NCT02076659; n=34) and the phase II trial (NCT02270632; n=23; As of May 2017), presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top